Many technologies have been mooted as equal to transurethral resection of the prostate (TURP) without gaining widespread acceptance owing to lack of randomized trials. The GreenLight laser system (American Medical Systems, Minnetonka, MN) gives an 80-W laser ablation system for photovaporization of the prostate (PVP) and here is compared to TURP in such a trial. One hundred and twenty patients are randomized to undergo TURP or PVP after evaluation, which is repeated at 1, 3, 6 and 12 months. Irrigation use, length of catherization time (LOC), length of hospital stay (LOS), blood loss, cost and operative time are also assessed. To date 87 patients are evaluable. In summary, both groups showed a significant increase in maximal flow rate (Q max ) from baseline (Po0.05). In the TURP group it increased from 8.7 to 17.9 ml/s (149%), and in the PVP group from 8.5 to 20.6 ml/s (167%). international prostrate symptom scores (IPS-scores) decreased from 25.4 to 11.1 in the TURP group (56.5%), and from 27.2 to 12.2 in the PVP group (54.08%). Similar trends were seen in relation to bother and quality of life scores. There was no difference in sexual function as measured by baseline sexual function questionnaires. LOC was significantly less in the PVP group (Po0.001), the mean for PVP being 13 h (range 0-24) vs 44.7 h for TURP (range 6-192). A similar situation was seen in relation to LOS (Po0.000000001), with the mean of the PVP group being 1.09 days (range 1-2) and the mean for the TURP group being 3.6 days (range 3-9). Adverse events were less frequent in the PVP group. Costs are also 22% less in the PVP group. This trial demonstrates that PVP is an effective technique when compared to TURP, producing equivalent improvements in flow rates and IPSS scores with markedly reduced LOS, LOC and adverse events. Long-term follow-up is being undertaken to ensure durability of these results.
Introduction
Transurethral resection of the prostate (TURP) has been the most durable and reliable endoscopic method of relieving lower urinary tract symptoms (LUTS) caused by bladder outlet obstruction (BOO) secondary to benign prostatic hyperplasia (BPH). It has been shown to markedly improve both objective (flow rates) and subjective (International Prostate Symptom Scores-IPSS) measures of BOO by 90-175% and 53-81% respectively. 1 This surgical procedure is one of the most common procedures performed today, with an estimated 400 000 TURPs being performed annually, at a cost of approximately $5 billion dollars. 2 However, TURP is not without its problems. Complications occur in up to 20% of patients including need for blood transfusion, infections, strictures, bladder neck stenosis, sexual problems and urinary retention and incontinence. 3 Allied to this, many men find the procedure, subsequent catherization and post-operative period painful, limiting from a quality of life point of view, and many are not satisfied with their result. In most hands the procedure requires an inpatient stay of at least overnight, if not longer, with significant patient inconvenience and cost to the health-care system. Given these limitations in what is an extremely common procedure, many alternatives have been looked at over the last 15 years. The most promising of these comes from the field of application of laser technology, with laser energy, in various manifestations and delivery systems, having been extremely well studied, with some forms being subjected to randomized trials. These include visual laser ablation of prostate 4 and holmium enucleation of the prostate. 5 Newer energy sources, laser technologies and methods of delivery should also be evaluated in a similar manner.
The GreenLight laser system utilizes a potassiumtitanyl-phosphate crystal to produce a light beam at a wavelength of 532 nm, which is preferentially taken up by the red haem moiety, at a power level of 80 W. This allows for tissue photovaporization, giving the procedure the name of Photoselective Vaporization of the Prostate (PVP). As well as vaporization of tissue, the system allows for tissue coagulation, but only to a depth of 1-2 mm, as its effective depth of action is 0.8 mm. 6 This system has been used to great effect for up to 7 years, with excellent functional results, short catherization times and inpatient stays, and minimal complications. 7 However, to date there has not been a formal randomized trial performed using the results of this technology against those from TURP. We undertook a randomized trial examining the outcomes of PVP as against those of TURP in the Royal Melbourne Hospital under the direction of Professor Tony Costello. 8 
Materials and methods
The trial was established in accordance with the American Urological Association guidelines of establishment of new technologies in the treatment of BPH. After clearance from the hospital ethics committee, 120 patients in total are to be recruited, randomized to PVP or TURP and evaluated in a prospective manner. All patients are recruited from those being referred with LUTS to the Urology outpatients of a major urban university hospital beginning in January 2004. Patients are screened to assess eligibility and those suitable are counselled as to the nature of the trial, fully informed consent is obtained and then they are randomly assigned to TURP or PVP. Inclusion criteria are listed in Table 1 and exclusion criteria in Table 2 . In short, patients had to be 50 years or greater with peak voiding flow rates less than or equal to 15 ml/s and IPSS scores of 12 or greater and not on oral anticoagulants. Residual postvoid urine volumes are also assessed. Platelet inhibitor use was not an exclusion criterion, if the medication could be safely stopped 10 days preoperatively. Patients with an indwelling catheter for acute retention, the presence of chronic retention or a neurogenic bladder were also excluded. Patients with known prostate cancer were excluded. Those with suspicion of prostate cancer (raised PSA and/or abnormal digital rectal exam) had to have that outruled by biopsy before enrolment. Alpha-blockade use before evaluation had to be ceased for 2 weeks. Those who met the initial inclusion criteria underwent estimation of prostate gland size by trans-rectal ultrasound (TRUS), and full urodynamic evaluation, including analysis of definitive obstruction using an AbramsGriffiths nomogram. All patients underwent full blood count analysis, urea and electrolytes and mid-stream urine testing. Preoperative bother scores, quality of life (QoL) scores and baseline sexual function questionnaires (BSFQ) were also collected.
All operative procedures were performed by registrars-in-training or fellows in the department, all of whom had performed between 35 and 325 TURPs and less than five laser prostatectomies each. This was performed to remove the expert bias that can be experienced in trials of new surgical procedures and to try and assess the ease of uptake of the PVP technology by the average urologist. TURP was undertaken in the standard manner through a 24 Ch resectoscope sheath, using a ValleyLab diathermy machine (ValleyLab, Boulder, CO, USA) and the passage of a three-way 22 Ch Foley catheter postoperatively, on continuous irrigation with saline. Irrigation was stopped when deemed appropriate by the registrar of the unit when the irrigant was rosé-coloured or clearer, and catheter removal was undertaken at the clinical discretion of the registrar, usually on the second postoperative morning. PVP was performed using an 80 W KTP laser using a GreenLight laser system, and a StarPulse quasicontinuous wave laser (American Medical Systems, Minnetonka, MN), emitting green light at a wavelength of 532 nm. A 600 mm laser fibre with a 701 lateral deflecting quartz element is used through the working channel of a 22.5 Ch continuous flow laser cystoscope using saline for irrigation. Catheters were left in-situ at the discretion of the operating surgeon. Intra and postoperative parameters that were measured included length of time of operation, amount of irrigation, number of bladder washouts, postoperative haemoglobin, LOC and LOS. Both groups received antibiotics at induction, and non-steroidal antiinflammatories and anticholinergics on discharge for use on an as-needed basis.
Patients were all followed up in the clinic at 6 weeks, 3, 6 and 12 months by two investigators in combination (DBH, PB). Repeat flow rates and IPSS scores, as well as QoL scores, bother and BSFQ scores are performed at each visit and a record of complications was noted. Prostate volume (measured by TRUS) and urodynamics are repeated at 6 and 12 months. Recently, we have begun to measure PSA at 6 months. Results are recorded on a Microsoft Excel spreadsheet (Microsoft, Seattle, WA, USA). Statistical analysis is undertaken again using Microsoft Excel software. Results are expressed as the mean plus or minus the s.d. of the group, and the statistical tool used is the Student's t-test, either paired or unpaired as appropriate. Statistical significance is taken if Po0.05.
Results
The full 120 patients have been randomized, but not followed out to the primary end point of 1 year, thus implying that the study has not achieved sufficient numbers to date to show the equivalence that it is powered to, so these data can only be viewed as preliminary data. However, statistical analysis is provided for these interim data. One hundred and eleven Table 3 . In summary, both groups showed a significant increase in maximal flow rate (Q max ) from baseline (Po0.0005). In the TURP group it increased from 8.9 to 18.7 ml/s (142.1%), and in the PVP group from 8.7 to 19.2 ml/s (148.8%). There was no statistical difference between the two groups in the increases seen, that is, both increases were equivalent. Likewise, in terms of decreases in IPSS, both groups showed a significant decrease of equal amounts (Po0.0000005) from baseline. Scores decreased from 25.4 to 11.1 in the TURP group (56.1%), and from 25.3 to 9.8 in the PVP group (60.2%). Postvoid residual volumes decreased in the TURP arm from 111 ml (range 0-476 ml) to 21 ml (0-165 ml) and in the PVP arm from 135 ml (range 0-787 ml) to 17 ml (range 0-147 ml). Similar trends in amelioration of symptoms were seen in relation to bother and QoL scores, with both groups showing equivalent and equal levels of improvement. There was no difference in sexual function as measured by BSFQ between pre and postoperative evaluation, nor between TURP and PVP.
LOC, LOS, litres of irrigation solution used, blood loss and overall cost are summarized in Table 4 . In summary, LOC was significantly less in the PVP group (Po0.001), the mean for PVP being 14 h (range 0-24) vs 44.7 h for TURP (range 6-192). LOC was defined as time to initial removal of catheter, and does not include any further catherization. A similar situation was seen in relation to LOS (Po0.000000001), with the mean of the PVP group being 1.1 days (range 1-2) and the mean for the TURP group being 3.3 days (range 3-9). Irrigation solution usage was markedly less in the PVP group, being 7.4 l (range 2-30), as against 22.4 l in the TURP group (range 10-64; Po0.00001). Blood loss as measured by serum haemoglobin levels on the first postoperative morning showed that both procedures did not have significant blood loss (TURP ¼ 1.5 g/dl, PVP ¼ 0.4 g/dl) compared to preop but that the change was statistically less with PVP (Po0.05). Cost was analysed by taking a random sample of five cases from each group and having costs assessed by the hospital's Clinical Costing Coordinator on a case-by-case basis. Added to this was the price of a laser fibre (AU$971) and an analysis of capital cost per case for both the base laser machine and the diathermy apparatus. This was performed by using the United Kingdom Government actuarial table, using a depreciation level of 3% per year and a zero resale value to calculate an equivalent annual cost and thus formulate a cost per year. This cost was then extrapolated to cost per procedure by calculating the cost if 163 procedures are performed per year. This was the number of endoscopic prostatectomies (TURP, PVP, etc.) performed in our unit in 2004. These figures show that PVP was 22% cheaper overall than TURP (physician's fees being equal).
Complications were seen in the two groups. There were more numerous significant complications noted in the TURP group. These included 16 patients who experienced clot retention on one or more occasions in the early postoperative period, and required manual bladder washouts, compared to two in the PVP group. One of these patients required a blood transfusion. Four patients in each group had sub-meatal strictures or bladder neck stenosis. All were treated easily with dilatation or bladder neck incision as appropriate, except for one patient from the TURP group, who required a meatotomy, and has withdrawn from further follow-up. One patient in the TURP group and three in the PVP group required re-resection for persistent symptoms and poor flow rates caused by residual adenomatous tissue. Two of the TURP group and one in the PVP group failed their trial of void and required recatherization for a further 4 weeks, after which they voided successfully. Seven of the TURP group, and five of the PVP group complained of dysuria significant enough to warrant being mentioned at the clinic at 6 weeks, and three patients (two TURP, one PVP) had a secondary haemorrhage requiring recatherization and inpatient admission. One PVP patient had postoperative retention, which settled with 48 h of catherization. There was one case of TUR syndrome in the TURP group, which required intensive treatment and intensive care unit admission.
Establishing a new standard
TURP has stood the test of time as an efficacious operative procedure for the relief of BOO secondary to BPH, and is recognized, with good reason, to be the 'gold standard' in this regard. However, as mentioned earlier, it is not without its drawbacks. In general, at least one night inpatient stay is required, if not more. Complication rates of up to 20% have been described. 3 The procedure itself is not easy to learn and most urologists would claim that one needs to have completed 50 or more TURPs before being comfortable with this technique. It is interesting to note that in the USA today the average number of TURPs being performed by a urologist 10 years into practise is 12-14, 9 implying that it may be difficult to maintain proficiency in this sometimes demanding procedure in this day and age. Many men suffer side-effects, which urologists regard as near-normal or expected such as prolonged dysuria, haematuria and retrograde ejaculation. Allied to this, the cost of the procedure plus inpatient stay is not inconsiderable. With these points in mind, surgeons have attempted to harness different technologies to simulate the positive results from TURP, but minimize the negative aspects of it. One of the most interesting of these has been the evolution of laser therapy as a proposed minimally invasive technique in treatment. One of the most important aspects of trying to establish a new standard of surgical technique is to apply the highest level of evidence examination to said technique, which is why the undertaking of a randomized controlled trial is vital, despite the difficulties and length of time involved in performing one. However, multicenter trials, case series comparisons and data from units with long-term follow-up such as those of Professor Reza Malek of the Mayo Clinic also add to the body of evidence supporting PVP as an excellent alternative to TURP. Of note, it is important that those undertaking any new procedure such as PVP be rigorously trained, and it is to the credit of the manufacturers of this technology that they recommend that any urologist starting out with PVP be trained by an accredited trainer and that they facilitate this in most parts of the world, and have a list of urologists that are deemed to be trained on their website. Accompanying this is the obvious point that a new technique should be rigorously audited and that individuals' results be available for public scrutiny and discussion. It is vital that if PVP is to rise to the heights of replacing TURP as a method of endoscopic prostatectomy that results are presented to both the public and the profession in a clear and transparent manner to allow for informed debate. However, the fact that over 200 000 PVP procedures have been performed worldwide in the space of a few short years with no reported mortalities to this author's knowledge lends credence to the fact that it is a safe technique. One other area of significant interest is that of the so-called learning curve. This is an extremely difficult area to quantify properly and often relies on the personal impression of the operating surgeon and the level of previous resection experience and the correct level of supervision during early cases. My own personal feeling is that one was confident of tackling smaller glands (o40 cm 3 ) with minimal median lobe volume safely after about five cases, but that one does not become proficient with larger or more complex glands until after about 20 cases. The patients in the current study were all operated on by surgeons with minimal laser experience to try to show ease of acquisition of the skills involved in this procedure. Essentially, a short mentorship period is usually sufficient to be able to perform PVP safely and, in general, effectively.
Overall, preliminary data from this first randomized trial of TURP vs PVP are very encouraging. Although firm conclusions cannot be drawn as of yet owing to the early nature of the results, what can be inferred to date is that PVP is equivalent to TURP in terms of decreasing IPSS and other measures of symptom severity, and increases flow rates to a similar degree. The procedure is day case-based, with much shorter admission times and LOCs, with subsequent real monetary savings, despite the apparent high cost of the equipment and consumables. Finally, significant complication rates are much less with PVP, and it is a safe and efficacious procedure, even in the hands of the relative novice.
TURP has served both urologists and their patients extremely well throughout the years. However, the rapid improvement in technology in every walk of life must also transfer into the area of urology, especially with so common a procedure as TURP. It is our belief that PVP performed with the GreenLight laser has significant potential and warrants further rigorous investigation in the treatment of symptomatic men with troublesome voiding symptoms secondary to BPH. It is hoped that commercial considerations will not overcome the virtues of proper clinical-based research in this area, allowing for a correct, accurate and unbiased appreciation of the role of this technology in the treatment of the obstructing prostate in the male.
